<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1619">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05140083</url>
  </required_header>
  <id_info>
    <org_study_id>FirstAHFujian13</org_study_id>
    <nct_id>NCT05140083</nct_id>
  </id_info>
  <brief_title>68Ga-NOTA Evans Blue PET/CT in Patients With Lymphatic System Related Diseases</brief_title>
  <official_title>68Ga-NOTA Evans Blue PET/CT in Patients With Lymphatic System Related Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Fujian Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the potential usefulness of 68Ga-NOTA Evans Blue (68Ga-NEB) positron emission&#xD;
      tomography/computed tomography (PET/CT) for the diagnosis of primary and efficacy assessment&#xD;
      in lymphatic system related diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with lymphatic system related diseases underwent 68Ga-NEB PET/CT either for a&#xD;
      primary diagnosis or for efficacy assessment. Anomalies were detected by visual analysis and&#xD;
      quantitative analysis of maximum standard uptake value (SUVmax). To compare the diagnostic&#xD;
      sensitivity of 68Ga-NEB PET/CT lymphatic imaging with other lymphatic imaging such as&#xD;
      99mTc-dextran for lymphatic system related diseases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual analysis of lymphatic patency</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>The bilateral lymphatic description on 68Ga-NEB PET/CT and lymphatic SPECT imaging were compared. The patency of lymphatic vessels (including lymphatic disruption, dermal distribution, and so on, results are indicated by 0 and 1) are shown in two imagings were recorded respectively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standardized uptake value (SUV)</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>Standardized uptake value (SUV) of 68Ga-NEB for each target lesion of subject.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic efficacy</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>The sensitivity of 68Ga-NEB PET/CT and lymphatic SPECT imaging were calculated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Positron-Emission Tomography</condition>
  <arm_group>
    <arm_group_label>68Ga-NOTA Evans Blue PET/CT in Patients with Lymphatic System Related Diseases</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 37-111 Mega-Becquerel (MBq) 68Ga-NOTA Evans Blue will be injected subcutaneously. PET/CT imaging will be performed at 5-30 min post- injection. Visual and quantitative method will be used to assess the PET/CT images.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Ga-NOTA Evans Blue</intervention_name>
    <description>Each subject receives a single subcutaneous injection of 68Ga-NOTA Evans Blue, and undergo PET/CT imaging within the specific time.</description>
    <arm_group_label>68Ga-NOTA Evans Blue PET/CT in Patients with Lymphatic System Related Diseases</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult population (aged between18 years and 80 years)&#xD;
&#xD;
          -  patients with suspected or new diagnosed or previously treated lymphatic system&#xD;
             related diseases&#xD;
&#xD;
          -  patients who had scheduled 68Ga-NEB PET/CT scan&#xD;
&#xD;
          -  patients who were able to provide informed consent (signed by participant, parent or&#xD;
             legal representative) and assent according to the guidelines of the Clinical Research&#xD;
             Ethics Committee&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with pregnancy&#xD;
&#xD;
          -  the inability or unwillingness of the research participant, parent or legal&#xD;
             representative to provide written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weibing Miao, MD</last_name>
    <phone>86-0591-87981618</phone>
    <email>miaoweibing@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meiyan Lin, MD</last_name>
    <phone>86-0591-87981619</phone>
    <email>linmeiyan_1@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weibing Miao, MD</last_name>
      <phone>+86 591 87981618</phone>
      <email>miaoweibing@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Meiyan Lin, MD</last_name>
      <phone>+86 591 87981619</phone>
      <email>linmeiyan_1@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 9, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Fujian Medical University</investigator_affiliation>
    <investigator_full_name>Weibing Miao, PhD</investigator_full_name>
    <investigator_title>Director, Department of Nuclear Medicine</investigator_title>
  </responsible_party>
  <keyword>Lymphatic System Related Diseases</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

